Together, these observations suggest that ovarian cancer patients whose tumor cells express reduced, and perhaps even undetectable levels of HER2 as assessed by today's diagnostic standards, may benefit from trastuzumab "priming." Our results further indicate that SKOV-3 may not be the most representative ovarian carcinoma-derived cell line for future preclinical studies of trastuzumab in EOC, despite the historic, and nearly exclusive use of this cell line as a model for EOC in previous preclinical studies on trastuzumab [34,50-60]. Here, ERBB2 is linked to ovarian cancer.